New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
09:15 EDTFTEK, BONT, JCP, FCEL, EJ, MYGN, ZBB, BYD, VIPS, LJPC, AEO, PLUGOn The Fly: Pre-market Movers
UP AFTER EARNINGS: FuelCell (FCEL), up 16%. Shares of alternative energy industry peers Plug Power (PLUG), up 9%, and ZBB Energy (ZBB), up 16%, are also higher in pre-market trading. ALSO HIGHER: Boyd Gaming (BYD), up 14% after activist investor Elliott disclosed a stake in the company that includes a 4.99% voting interest and a total economic exposure of 7%... La Jolla Pharmaceutical (LJPC), up 71% after announcing that its Phase 2 trial of GCS-100 in chronic kidney disease reached its primary and key secondary endpoints... J.C. Penney (JCP), up 7.5% following upgrade to Buy rating at Citigroup. DOWN AFTER EARNINGS: American Eagle (AEO), down 5%... Bon-Ton Stores (BONT), down 5.7%... Fuel Tech (FTEK), down 20%. ALSO LOWER: Myriad Genetics (MYGN), down 8% after company denied request for injunction against rival... Vipshop (VIPS), down 4% following downgrade to Neutral rating at Goldman.
News For FCEL;PLUG;BYD;JCP;AEO;ZBB;BONT;LJPC;MYGN;FTEK;VIPS;EJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 20, 2015
05:17 EDTMYGNMyriad EMPATHY-P clinical study results to be highlighted at annual congress
Myriad Genetics announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30th Annual Congress of the European Association of Urology. The EMPATHY-P study evaluated the Prolaris test on 525 patient biopsy samples to determine the aggressiveness of prostate cancer in these newly diagnosed patients from five European countries including: Italy, Germany, Spain, Switzerland and the UK. The patients' biopsy samples also were evaluated using standard clinical pathology methods, which were then compared to the Prolaris test results. The EMPATHY-P data showed, overall, that the Prolaris test found 42% of the European men evaluated had a risk profile that was either lower or higher than would be expected using clinical pathology. Interestingly, this finding is consistent with the previously published U.S. Prostate Biopsy Research study, which found 51% of U.S. patients had a risk profile that differed from clinical pathology.
March 19, 2015
15:39 EDTBYDBoyd Gaming CEO says trajectory of downtown Las Vegas promising
Boyd Gaming CEO is speaking on CNBC.
07:21 EDTEJE-House price target lowered to $13 from $16 at Brean Capital
Subscribe for More Information
March 18, 2015
13:30 EDTJCPJ.C. Penney trades lower after news of executive departures
Subscribe for More Information
08:06 EDTLJPCLa Jolla announces initiation of Phase 2b trial of GCS-100
Subscribe for More Information
06:40 EDTEJE-House sees FY15 revenue $1.05B-$1.1B, consensus $1.05B
Subscribe for More Information
06:39 EDTEJE-House reports Q4 EPS 14c, consensus 19c
Reports Q4 revenue $312.3M, consensus $281.01M.
March 17, 2015
15:41 EDTJCPJ.C. Penney General Counsel Janet Dhillon leaving, Bloomberg says
Subscribe for More Information
15:18 EDTEJNotable companies reporting before tomorrow's open
Subscribe for More Information
10:25 EDTPLUGPlug Power says can reach $500M in revenue in the next 4-5 years
Subscribe for More Information
10:13 EDTPLUGPlug Power reports Q4 adjusted EPS 8c, consensus (4c)
Subscribe for More Information
10:08 EDTPLUGPlug Power says sees over $100M in revenue for 2015, consensus $107.13M
Says plans to recognize over $100M in revenue for 2015, consensus $107.13M. Says targeting $200M in bookings, with approx. 75% coming from repeat customers. In 2015, also plans to continue to increase gross margins, continue investment in expanding hydrogen offering. Says company is financially secure. Comments made on the Q4 earnings conference call. Plug Power is down 8.36% to $2.52 in morning trading.
09:25 EDTPLUGOn The Fly: Pre-market Movers
Subscribe for More Information
07:53 EDTAEOMatson American Eagle Jack Henry named triple play at Oppenheimer
Subscribe for More Information
07:18 EDTMYGNMyriad Genetics announces collaboration expansion with BioMarin
Myriad Genetics (MYGN) announced an expansion of the company's collaboration with BioMarin Pharmaceutical (BMRN). Under the expanded collaboration, BioMarin will use Myriad's myChoice HRD companion diagnostic test to prospectively identify patients with metastatic breast, ovarian and potentially other tumor types that may be sensitive to talazoparib. Financial terms were not disclosed.
07:06 EDTPLUGPlug Power reports Q4 EPS (4c), consensus (4c)
Subscribe for More Information
06:57 EDTJCPJ.C. Penney CMO leaves company, effective immediately, AdAge reports
Subscribe for More Information
March 16, 2015
17:23 EDTFTEKFuel Tech reports Q4 adjusted EPS (4c), consensus 2c
Subscribe for More Information
16:40 EDTLJPCLa Jolla reports Q4 EPS (45c), consensus (37c)
Subscribe for More Information
15:26 EDTPLUGNotable companies reporting before tomorrow's open
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use